FF Participants, the PTT versus Anti-Xa entry has morphed into a discussion of anti-Xa nomenclature, so I’ve decided to start a new thread. Be sure to link back to the prior thread to see where this is coming from.
From Dr. Favaloro: Couldn’t resist adding my support to this. We have moved away from “anti-Xa” ordering, not only due to this previously causing confusion with the ‘factor X’ assay, but also because we now use this method to assess UFH, LMWH, apixaban, rivaroxaban, etc; so, clinicians can no longer order ‘anti-Xa‘ as an electronic order–they have to order the specific drug. If they don’t know what drug is onboard (e.g., emergency admission with abnormal coagulation studies and a suspicion of anticoagulant drug), they can chose ‘unknown anticoagulant drug’ level and we can try to work it out together. We still get paper requests for ‘anti-Xa‘, in which case (should we not be able to clarify the drug with the requesting clinician) the default is our LMWH assay, with this being advised to the clinician in the test report. It takes much effort to change entrenched ordering practice. regards, Emmanuel.